CBP-501
Description
CBP-501, a cell-permeable calmodulin-binding peptide and a G2-abrogating drug candidate, inhibits the activity of multiple Ser216-specific kinases, such as MAPKAP-K2, C-Tak1, CHK1 and CHK2, with IC50 values of 0.9 ??M, 1.4 ??M 3.4 ??M and 6.5 ??M, respectively. CBP-501 is used for various types of cancer.
Product Information
| Product Name | CBP-501 |
| Molecular Weight | 1929.06 |
| Formula | C86H122F5N29O17 |
| CAS Number | 565434-85-7 |
| Appearance | Solid |
| Color | White to off-white |
| Sequence | d({4-Bz-Phe}-Ser-Trp-Ser-{pentafluoro-Phe}-{Cha}-Arg-Arg-Arg-Gln-Arg-Arg) |
| Sequence Shortening | d({4-Bz-Phe}-SWS-{pentafluoro-Phe}-{Cha}-RRRQRR) |
| Storage | Sealed storage, away from moisture Powder -80??C 2 years -20??C 1 year *In solvent : -80??C, 6 months; -20??C, 1 month (sealed storage, away from moisture) ???? & ??Ʒ???? ???ȣ? 99.75% ѡ?????Σ? HY-16129-80**** Data Sheet (525 KB) SDS (252 KB) COA (297 KB)RP-HPLC (109 KB)MS (247 KB) ??Ʒʹ??ָ?? (1538 KB) ?ο????? . Enzler T, et al. A multicenter, randomized phase 2 study to establish combinations of CBP501, cisplatin and nivolumab for ??3rd-line treatment of patients with advanced pancreatic adenocarcinoma. Eur J Cancer. 2024 Apr;201:113950. ? . Shi-Ken Sha, et al. Cell cycle phenotype-based optimization of G2-abrogating peptides yields CBP501 with a unique mechanism of action at the G2 checkpoint. Mol Cancer Ther. 2007 Jan;6(1):147-53. ? |
